Epigenetic regulation in therapeutic human pancreatic beta cell proliferation
治疗性人胰腺β细胞增殖的表观遗传调控
基本信息
- 批准号:10192020
- 负责人:
- 金额:$ 15.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalATAC-seqAcademiaAffectAgonistArchitectureBeta CellBiochemistryBioinformaticsBiological AssayBlindnessCell ProliferationCellsCellular biologyCessation of lifeChIP-seqCharacteristicsChromatinChromatin StructureChronicChronic DiseaseDataData AnalysesDevelopment PlansDiabetes MellitusDialysis procedureDiseaseDoctor of PhilosophyDrug TargetingEnvironmentEpigenetic ProcessFacultyFutureGCG geneGenesGeneticGermanyGoalsGraphHigh-Throughput Nucleotide SequencingHistonesHumanHypertensionImmuneImpaired fasting glycaemiaInstitutesInsulinInsulin-Dependent Diabetes MellitusIslets of Langerhans TransplantationKidney FailureLeadershipLeftLightMassive Parallel SequencingMeasuresMediatingMeleagris gallopavoMentorsMetabolic DiseasesMetabolismMolecularMolecular BiologyMolecular GeneticsMyocardial InfarctionNatural regenerationNon-Insulin-Dependent Diabetes MellitusObesityOrgan DonorPancreasPancreas TransplantationPathway interactionsPatternPharmaceutical PreparationsPharmacologyPharmacotherapyPopulationProgram DevelopmentProliferatingPropertyReportingResearchResearch PersonnelResidual stateRisk FactorsRoleScientistStrokeStructure of beta Cell of isletTechnologyTherapeuticTrainingTransforming Growth Factor betaTransplantationUniversitiesWorkWritingbasecareercareer developmentcell regenerationchromatin immunoprecipitationchromosome conformation capturecostdiabetes mellitus therapydrug developmentepigenetic regulationexperienceexperimental studyinhibitor/antagonistinstructorisletmedical schoolsmembermolecular sequence databasenew therapeutic targetnext generation sequencingnon-diabeticnovelnovel therapeutic interventionnovel therapeuticsprematurereceptorregenerativeregenerative cellresponsesingle-cell RNA sequencingskillsstem cellstargeted treatmenttranscriptome
项目摘要
Project Summary
This is a K-01 application for Esra Karakose, PhD. Her overarching goal is discovering novel therapeutic
approaches for diabetes. This proposal investigates the role of epigenetics in the control of human beta cell
replication, aiming to identify novel pathways and drug targets that will enable human beta cell regeneration.
Candidate. Dr. Karakose is a junior faculty member (Instructor) at the Diabetes Obesity and Metabolism Institute
at Icahn School of Medicine at Mount Sinai. She holds a M.Sc degree from Bilkent University, Turkey, and a
Ph.D degree from the prestigious Max Planck Institute for Biochemistry, Germany. Her extensive experience in
molecular biology and genetics as well as the expertise she developed in beta cell biology during her postdoctoral
work have prepared her to successfully accomplish the objectives of this proposal. Her career development plan
includes four training goals all which will be instrumental to help her transition into an independent research
career: 1) Acquire advanced programming skills to better analyze and interpret data; 2) Gain hands-on
experience in single cell RNA-seq experiments and data analysis; 3) Develop Chromatin Conformation Capture
experiments and apply bioinformatics analysis; and, 4) Develop writing and leadership skills.
Mentors/Environment. Dr. Karakose will be mentored by her primary mentor, Dr. Andrew Stewart, and two
additional very accomplished and complimentary scientists. Dr. Martin Walsh is a prominent scientist in genetics,
epigenetics and pharmacology, and Dr. Sebra is a pioneer in next-gen sequencing technologies and analysis.
Mount Sinai provides state-of-the-art lab facilities as well as a highly dynamic scientific environment, thereby
creating an excellent opportunity for Dr. Karakose to thrive as a researcher.
Research. Current approaches to reverse beta cell loss in diabetes are limited: islet transplantation, whole
pancreas transplantation and stem cell-based strategies for transplantable beta cells. However, many hurdles
are associated with these approaches, including an insufficient number of organ donors, immune rejection, lack
of successful implementation in the case of stem cell-based strategies, and excessive cost. A promising
alternative is beta cell regenerative drug therapies. This proposal will be key to understand the mechanisms of
actions of the current beta cell regenerative drugs, all of which work through mechanisms involving beta cell
epigenetics. Moreover, it will provide crucial information for identifying novel drug targets for beta cell
proliferation. Aim 1 will define the open chromatin regions and histone mark signatures in of human pancreatic
beta cells treated with regenerative drugs. Aim 2 will determine epigenetic properties of proliferating beta cells
with single cell approaches. More specifically, Aim 2a will define the transcriptomes of the subset of human
pancreatic beta cell populations with the proliferative capacity, whereas Aim 2b will define 3D chromatin
architecture in proliferating human pancreatic beta cells.
项目摘要
这是Esra Karakose博士的K-01申请表。她的首要目标是发现新的治疗方法
糖尿病的治疗方法该建议调查了表观遗传学在控制人类β细胞中的作用,
复制,旨在确定新的途径和药物靶点,使人类β细胞再生。
候选人Karakose博士是糖尿病肥胖和代谢研究所的初级教员(讲师)
在西奈山伊坎医学院她拥有土耳其Bilkent大学的理学硕士学位,
博士学位,著名的马克斯普朗克生物化学研究所,德国。她的丰富经验,
分子生物学和遗传学以及她在博士后期间在β细胞生物学方面的专业知识
她的工作使她做好了准备,成功地实现了这项建议的目标。她的职业发展计划
包括四个培训目标,所有这些都将有助于帮助她过渡到独立研究
职业:1)获得高级编程技能,以更好地分析和解释数据; 2)获得动手能力
具有单细胞RNA-seq实验和数据分析经验; 3)开发染色质构象捕获
实验和应用生物信息学分析;和,4)发展写作和领导能力。
导师/环境。Karakose博士将由她的主要导师Andrew Stewart博士指导,
其他非常有成就的科学家。马丁沃尔什博士是遗传学领域的杰出科学家,
Sebra博士是下一代测序技术和分析的先驱。
西奈山提供最先进的实验室设施以及高度动态的科学环境,从而
为Karakose博士作为一名研究人员创造了一个很好的机会。
Research.目前逆转糖尿病中β细胞丢失的方法是有限的:胰岛移植,整体
胰腺移植和基于干细胞的可移植β细胞策略。然而,许多障碍
与这些方法有关,包括器官捐献者数量不足,免疫排斥,缺乏
成功实施基于干细胞的策略的可能性,以及过高的成本。一个有前途
替代疗法是β细胞再生药物疗法。这一提议将是理解
目前的β细胞再生药物的作用,所有这些都通过涉及β细胞的机制发挥作用,
表观遗传学此外,它将为确定新的β细胞药物靶点提供重要信息
增殖目的1将确定人胰腺癌细胞中开放的染色质区域和组蛋白标记物
用再生药物治疗的β细胞目的2将确定增殖β细胞的表观遗传特性
单细胞方法。更具体地说,目标2a将定义人类基因组亚组的转录组。
具有增殖能力的胰腺β细胞群,而Aim 2b将定义3D染色质
在增殖的人类胰腺β细胞中的结构。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Esra Karakose其他文献
Esra Karakose的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Esra Karakose', 18)}}的其他基金
Epigenetic regulation in therapeutic human pancreatic beta cell proliferation
治疗性人胰腺β细胞增殖的表观遗传调控
- 批准号:
10364701 - 财政年份:2021
- 资助金额:
$ 15.29万 - 项目类别:
Epigenetic regulation in therapeutic human pancreatic beta cell proliferation
治疗性人胰腺β细胞增殖的表观遗传调控
- 批准号:
10532768 - 财政年份:2021
- 资助金额:
$ 15.29万 - 项目类别:
相似国自然基金
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
- 批准号:62302218
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
- 批准号:82001520
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
- 批准号:81802809
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
- 批准号:31802046
- 批准年份:2018
- 资助金额:27.0 万元
- 项目类别:青年科学基金项目
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
- 批准号:31801915
- 批准年份:2018
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
- 批准号:31871331
- 批准年份:2018
- 资助金额:59.0 万元
- 项目类别:面上项目
相似海外基金
Project #2 Integrated single-nucleus multi-omics (ATAC-seq+RNA-seq or chromatin accessibility + RNA-seq) of human TGs
项目
- 批准号:
10806548 - 财政年份:2023
- 资助金额:
$ 15.29万 - 项目类别:
A transposase system for integrative ChIP-exo and ATAC-seq analysis at single-cell resolution
用于单细胞分辨率综合 ChIP-exo 和 ATAC-seq 分析的转座酶系统
- 批准号:
10210424 - 财政年份:2018
- 资助金额:
$ 15.29万 - 项目类别:
EAPSI: Developing Single Nucleus ATAC-seq to Map the Ageing Epigenome
EAPSI:开发单核 ATAC-seq 来绘制衰老表观基因组图谱
- 批准号:
1714070 - 财政年份:2017
- 资助金额:
$ 15.29万 - 项目类别:
Fellowship Award
A cloud-based learning module to analyze ATAC-seq and single cell ATAC-seq data
基于云的学习模块,用于分析 ATAC-seq 和单细胞 ATAC-seq 数据
- 批准号:
10558379 - 财政年份:2001
- 资助金额:
$ 15.29万 - 项目类别: